Wednesday, June 20
Continental Breakfast and Meet-the-Expert Roundtable Session 2
7:00 a.m.-8:00 a.m.
Session 5: How Does the Tumor Microenvironment Influence Pancreatic Cancer?
Session Chairperson: Sunil R. Hingorani, Fred Hutchinson Cancer Research Center, Seattle, WA
8:00 a.m.-10:00 a.m.
Dynamic and reciprocal force regulation of tumor progression
Valerie M. Weaver, University of California San Francisco Medical Center, San Francisco, CA
Inflammation and cancer: reprogramming the immune microenvironment as an anti-cancertherapeutic strategy
Lisa M. Coussens, OHSU Knight Cancer Institute, Portland, OR
Immune surveillance and CD40 therapy of pancreatic cancer in mice and humans
Robert H. Vonderheide, Abramson Cancer Center of University of Pennsylvania, Philadelphia, PA
Macropinocytosis as a mechanism of amino acid supply *
Cosimo Commisso, New York University School of Medicine, New York, NY
10:00 a.m.-10:30 a.m.
Session 6: Can KRAS be Defeated?
Session Chairperson: Channing J. Der, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC
10:30 a.m.-12:30 p.m.
Targeting K-Ras for the treatment of pancreatic cancer
Stephen W. Fesik, Vanderbilt University School of Medicine, Nashville, TN
Functional genomics and KRAS-driven cancers
William C. Hahn, Dana-Farber Cancer Institute, Boston, MA
Targeting unique dependencies of RAS mutant tumors
Julian Downward, Cancer Research UK, London, England
Oncogenic ras requires stimulation for activity sufficient to initiate a feed-forward inflammatory mechanism capable of inducing pancreatic diseases including pancreatitis and cancer *
Craig D. Logdson, University of Texas MD Anderson Cancer Center, Houston, TX
Poster Session B / Lunch
12:30 p.m.-2:30 p.m.
Session 7: What Are the Promising Preclinical and Clinical Advances in Pancreatic Cancer?
Session Chairperson: Margaret A. Tempero, University of California, San Francisco, CA
2:30 p.m.-4:30 p.m.
Targeting cancer stem cells in pancreatic cancer
Diane M. Simeone, University of Michigan Hospital and Health Systems, Ann Arbor, MI
Altering drug delivery in pancreatic cancer: Development and clinical translation of smoothened inhibitors
Kenneth P. Olive, Columbia University Irving Comprehensive Cancer Center, New York, NY
How much gemcitabine reaches the target... and does it matter?
Duncan I. Jodrell, CRUK Cambridge Research Institute, Cambridge, England
Clonal profiling of prospectively collected primary pancreatic ductal adenocarcinomas *
Michael T. Barrett, Translational Genomics Research Institute, Scottsdale, AZ
4:30 p.m.-5:00 p.m.
Session 8: Are There New Ways to Prevent or Treat Pancreatic Cancer?
Session Chairperson: Anil K. Rustgi, Abramson Cancer Center of University of Pennsylvania, Philadelphia, PA
5:00 p.m.-7:00 p.m.
Autophagy, metabolism, and pancreatic cancer
Alec C. Kimmelman, Dana-Farber Cancer Institute, Boston, MA
Regulation of metabolism to support tumor growth
Matthew G. Vander Heiden, Massachusetts Institute of Technology, Cambridge, MA
Microenvironment and pancreatic cancer
Roland M. Schmid, Klinikum rechts der Isar, Munich, Germany
Targeted therapy for pancreatic cancer *
Sanjay Awasthi, Beckman Research Institute, City of Hope, Duarte, CA
7:00 p.m.-8:30 p.m.
Keynote Presentation and Discussion: Progress Ahead for Pancreatic Cancer
8:30 p.m.-10:00 p.m.
Mila McCurrach, The Lustgarten Foundation, Bethpage, NY
David A. Tuveson, The Lustgarten Foundation, Bethpage, NY
Julie M. Fleshman, Pancreatic Cancer Action Network, Manhattan Beach, CA
Targeting KRAS directly
Frank McCormick, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA
Kras-directed anabolic processes in PDAC tumor maintenance
Ronald A. DePinho, University of Texas MD Anderson Cancer Center, Houston, TX